Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;52(7):1159-1165.
doi: 10.1111/1346-8138.17753. Epub 2025 Apr 24.

Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases

Limin Dou  1 , Fuying Chen  1 , Wei He  1 , Jianbo Wang  2 , Chenfei Wang  1 , Xiaotian Chen  3 , Xiaomin Peng  4 , Liuhui Wang  1 , Ying Ye  1 , Ming Li  1
Affiliations

Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases

Limin Dou et al. J Dermatol. 2025 Jul.

Abstract

Dystrophic epidermolysis bullosa (DEB) is a genetic skin disease with limited therapeutic options for managing pruritus. This study retrospectively evaluated the efficacy and safety of Dupilumab monotherapy in patients with DEB suffering from severe pruritus. DEB patients treated with Dupilumab between June 2021 and June 2023 were reviewed. DEB severity and pruritus intensity were assessed using the Birmingham Epidermolysis Bullosa Severity (BEBS, range 0-100) scores and the Numerical Rating Scale (NRS, range 0-10), respectively. A linear mixed model was used to evaluate the changes in NRS scores of Dupilumab monotherapy over time. The Wilcoxon signed-rank test was used to compare the differences in BEBS scores between pretreatment and posttreatment. Statistical significance was defined as p < 0.05. Eight patients were included (four males and four females; aged 5-38 years). Subtypes included severe (n = 4), intermediate (n = 2), pruriginosa RDEB (n = 1), or pruriginosa DDEB (n = 1). The baseline NRS scores averaged 8.75 ± 1.04, with significant reductions of 58.51%, 60.00%, and 49.94% at 4, 8, and 12 weeks, respectively (p < 0.001). The mean BEBS score at baseline was 35.36 ± 21.47, decreased by 22.29% at 12 weeks (p = 0.049), while the mean area of damaged skin score was 19.63 ± 1.71 at baseline, decreased by 31.23% after 12 weeks (p = 0.048). The mean duration of Dupilumab treatment was 44.50 (12-130) weeks. One DDEB-Pr patient discontinued Dupilumab for planned conception, with no adverse effects reported for the pregnant woman or newborn. Dupilumab appears to be a safe and effective treatment for pruritus in patients with DEB. Preliminary findings also support its potential use in women of reproductive age. Further larger prospective studies are needed to confirm these results.

Keywords: Dupilumab; dystrophic epidermolysis bullosa; pruritus; women of reproductive age; wound.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. F. Chen, R. Wei, D. Deng, et al., “Genotype and Phenotype Correlations in 441 Patients With Epidermolysis Bullosa From China,” Journal of the European Academy of Dermatology and Venereology 37, no. 2 (2023): 411–419.
    1. J. A. Feinstein, A. L. Bruckner, B. Chastek, A. Anderson, and J. Roman, “Clinical Characteristics, Healthcare Use, and Annual Costs Among Patients With Dystrophic Epidermolysis Bullosa,” Orphanet Journal of Rare Diseases 17, no. 1 (2022): 367.
    1. C. Danial, R. Adeduntan, E. S. Gorell, et al., “Prevalence and Characterization of Pruritus in Epidermolysis Bullosa,” Pediatric Dermatology 32, no. 1 (2015): 53–59.
    1. J. E. Mellerio, E. I. Pillay, L. Ledwaba‐Chapman, et al., “Itch in Recessive Dystrophic Epidermolysis Bullosa: Findings of PEBLES, a Prospective Register Study,” Orphanet Journal of Rare Diseases 18, no. 1 (2023): 235.
    1. F. J. Munoz‐Bellido, E. Moreno, and I. Davila, “Dupilumab: A Review of Present Indications and Off‐Label Uses,” Journal of Investigational Allergology & Clinical Immunology 32, no. 2 (2022): 97–115.

MeSH terms